Clinical Trials Logo
  1. Home
  2. Cancer of Unknown Primary Site
  3. NCT03278600

Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary

Cancer of Unknown Primary Site Clinical Trial

Official title:
The Value of Tissue-of-origin (ORIGIN-PanCA○R) Profiling in Predicting Primary Site and Directing Therapy in Patients With Cancer of Unknown Primary: a Prospective Randomized Controlled Study

Clinical Trial Summary

This study is designed to evaluate the value of tissue-of-origin (ORIGIN-PanCA○R) profiling in predicting primary site and directing therapy in patients with cancer of unknown primary.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03278600
Study type Interventional
Source Fudan University
Contact
Status Completed
Phase Phase 3
Start date September 18, 2017
Completion date March 18, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study N/A
Completed NCT03053466 - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Active, not recruiting NCT04750109 - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting NCT04952103 - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting NCT04969835 - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Phase 1
Active, not recruiting NCT03498521 - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Phase 2
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Recruiting NCT05263700 - FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary N/A
Active, not recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Completed NCT05841966 - Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary N/A
Recruiting NCT04131621 - Nivolumab/Ipilimumab in Second Line CUP-syndrome Phase 2
Recruiting NCT04459273 - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Phase 1
Active, not recruiting NCT05024968 - Sintilimab in Cancer of Unknown Primary Phase 2